Kymera Therapeutics

Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant B Cell Lymphoma at the 15th International Conference on Malignant Lymphoma

Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases

BOSTON, MA and CAMBRIDGE, MA – May 15, 2019 – Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Kymera Therapeutics today announced that the two companies have entered into a four-year strategic research and development collaboration to advance small molecule protein degraders against multiple targets.  The collaboration will leverage Kymera’s expertise in targeted protein degradation and its proprietary PegasusTM drug discovery platform and Vertex’s scientific, clinical, and regulatory capabilities to accelerate the development of first-in-class medicines for people with serious diseases.

Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant Lymphoma at Late-Breaking Session of the American Association for Cancer Research Annual Meeting

Cambridge, Mass. (March 29, 2019) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, will present new preclinical data for its first-in-class oral IRAK4 protein degrader, KYM-001, in MYD88-mutant lymphoma. Data will be presented  in a late-breaking research session at the American Association for Cancer Research Annual Meeting on April 3 from 8 a.m. – 12 p.m. (Poster #18, Session: Experimental and Molecular Therapeutics 2). The study showed that KYM-001 led to highly selective degradation of IRAK4 and tumor regression upon oral dosing, both alone and in combination with BTK inhibition.

Kymera Therapeutics Announces Expansion of Scientific Advisory Board to Advance Pre-Clinical Molecules Toward the Clinic

Cambridge, Mass. (Dec. 18, 2018) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, today announced the expansion of its Scientific Advisory Board (SAB) to support development of the company’s Pegasus platform and advancement of its small molecule-based protein degrader therapeutics into the clinic. The board is comprised of world-class scientists and clinicians, including experts in proteomics, human genetics, chemistry, E3 ligase biology and translational and clinical research.

Kymera Therapeutics Presents First Validation of IRAK4 Protein Degraders in MYD88-Mutant Lymphoma

Cambridge, Mass. (Dec. 3, 2018) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, today announced research demonstrating preclinical activity of the company’s first-in-class heterobifunctional small molecules to specifically degrade IRAK4 in MYD88 (myeloid differentiation primary response 88)-mutant lymphoma. Data were presented at the 60th Annual Meeting of the American Society of Hematology (ASH) in San Diego (Poster #2593, Session 625, Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster II).

Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology

Cambridge, Mass. (Nov. 13, 2018) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, announced today that it has completed a $65 million Series B financing.  The financing will support the advancement of its lead asset into clinical development, and to progress its therapeutic pipeline in oncology and immunology.  The financing was co-led by 6 Dimensions Capital, Bessemer Venture Partners, and Pfizer Ventures with participation by MRL Ventures Fund, Sanofi Ventures, Hatteras Venture Partners, and Aju IB Investment, in addition to Kymera’s Series A investors. The company also announced Wei Li, PhD, of 6 Dimensions Capital, Andrew Hedin of Bessemer Venture Partners, and Elaine Jones, PhD, of Pfizer Ventures, will join Kymera Therapeutics’ Board of Directors.

Chemical & Engineering News: Targeted protein degraders are redefining how small molecules look and act

Read the full article on Targeted protein degraders

Kymera Therapeutics Appoints Industry Veteran Mark E. Nuttall, Ph.D., as Chief Business Officer

Cambridge, Mass. (February 6, 2018) – Kymera Therapeutics LLC, a biotechnology company pioneering targeted-protein degradation as a transformative new approach to creating breakthrough medicines for patients, today announced the appointment of industry veteran Mark Nuttall, Ph.D., as chief business officer. Dr. Nuttall joins Kymera from Sanofi Genzyme where he led business development and licensing for Immunology and Inflammation and Neuroscience. The company also announced the appointment of Don Nicholson, Ph.D., CEO of Nimbus Therapeutics, to its Board of Directors.

Kymera Therapeutics Announces Series A to Advance Novel Therapeutic Modality and Develop Innovative Therapies

Cambridge, Mass. (Dec. 18, 2018) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, today announced the expansion of its Scientific Advisory Board (SAB) to support development of the company’s Pegasus platform and advancement of its small molecule-based protein degrader therapeutics into the clinic. The board is comprised of world-class scientists and clinicians, including experts in proteomics, human genetics, chemistry, E3 ligase biology and translational and clinical research.